Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced?
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cardiology and Cardiovascular Medicine,Physiology,Internal Medicine
Reference73 articles.
1. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.;N Engl J Med,2000
2. Telmisartan, ramipril, or both in patients at high risk for vascular events.;ONTARGET Investigators, Yusuf;N Engl J Med,2008
3. Investigators, Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.;Lancet,2008
4. Telmisartan to prevent recurrent stroke and cardiovascular events;Yusuf;N Engl J Med,2008
5. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.;Lancet,2007
Cited by 91 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. New European Guidelines 2023 for Hypertension: When and Why Should We Think About Sleep Apnea?;Archivos de Bronconeumología;2024-02
2. High residual cardiovascular risk after lipid-lowering: prime time for Predictive, Preventive, Personalized, Participatory, and Psycho-cognitive medicine;Frontiers in Cardiovascular Medicine;2023-10-16
3. Comparison between visit-to-visit office and 24-h blood pressure variability in treated hypertensive patients;Journal of Hypertension;2023-10-09
4. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension;Journal of Hypertension;2023-09-26
5. Sympathetic modulation as a goal of antihypertensive treatment: from drugs to devices;Journal of Hypertension;2023-09-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3